Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice

Last updated: March 4, 2024
Sponsor: University of Oklahoma
Overall Status: Completed

Phase

N/A

Condition

Neoplasms

Blood Cancer

Hematologic Neoplasms

Treatment

Blood and/or platelet transfusion

Complete blood count (CBC) collection

Clinical Study ID

NCT04454723
OU-SCC-PalliativeQOL
  • Ages > 18
  • All Genders

Study Summary

The purpose of this pilot research study is to evaluate the effectiveness of blood and platelet transfusions in improving symptoms and quality of life of patients enrolled in hospice.

Eligibility Criteria

Inclusion

Patients >= 18 years irrespective of their race, sex and/or other medical history. Inclusion Criteria:

  • All patients >= 18 years with a primary diagnosis of acute myeloid leukemia (AML),acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronicmyelomonocytic leukemia (CMML), "high risk" Non-Hodgkin's Lymphoma (NHL), multiplemyeloma (MM) and Myelodysplastic Syndrome (MDS) with a life expectancy of < 6 monthswho are transfusion dependent. Criteria for transfusion dependence is SymptomQuestionnaire symptom grade 2 or higher. The Symptom Questionnaire is based on CTCAE (Common Terminology Criteria for Adverse Events) v5.0, with criteria modified forpalliative care patients.
  • Patients wanting to enroll in hospice.
  • Availability of peripheral IV access line or patient agrees to have semi-permanent IVline placed.

Exclusion

Exclusion Criteria:

  • Patients with > 6-month survival.
  • Patients unwilling to go on hospice.
  • Patients with antibodies to blood or platelets that would preclude ability to giveblood/platelets without prolonged blood typing and or need for anti-HLA platelets.

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: Blood and/or platelet transfusion
Phase:
Study Start date:
August 14, 2020
Estimated Completion Date:
August 17, 2023

Study Description

This is a non-randomized pilot study to investigate the feasibility of symptom-based blood transfusion in patients with hematologic malignancies enrolling in hospice care.

The study will be a case series involving OU Medical Center (OUMC). Patients will be identified at the University of Oklahoma/Stephenson Cancer Center (OU-SCC) where investigators performing the study will consent and monitor patients. Integris Home Hospice agency will provide hospice patients with blood transfusions in those willing to participate, and the Oklahoma Blood Institute (OBI) will provide the hospice patients with palliative transfusions at home at no cost to the patient, including blood products, transfusion testing, infusions and the nursing staff.

This will be a pilot project including 20 consented patients with hematologic malignancies enrolling in hospice through Integris Home Hospice. The transfusions received will be determined by the hospice team, and will not be based on objective symptom based guidelines. Patients will have the option to either be enrolled on this clinical trial, where they may receive home based blood or platelet transfusions, or be enrolled in any other hospice of their choosing, including the other hospice that will provide home based transfusions. Information will be collected regarding symptoms, Hospice QOL scores and transfusion use, reactions, and time in hospice. Data will be collected until death.

Connect with a study center

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma 73117
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.